These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9643057)

  • 1. Scaling of movement velocity: a measure of neuromotor retardation in individuals with psychopathology.
    Caligiuri MP; Lohr JB; Ruck RK
    Psychophysiology; 1998 Jul; 35(4):431-7. PubMed ID: 9643057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.
    Caligiuri MP; Teulings HL; Filoteo JV; Song D; Lohr JB
    Hum Mov Sci; 2006 Oct; 25(4-5):510-22. PubMed ID: 16647772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of sensorimotor integration during locomotion toward a target in Parkinson's disease.
    Almeida QJ; Frank JS; Roy EA; Jenkins ME; Spaulding S; Patla AE; Jog MS
    Neuroscience; 2005; 134(1):283-93. PubMed ID: 15950389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
    Mongeon D; Blanchet P; Messier J
    Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Computerized method for arm movement assessment in Parkinson's disease and cerebellar syndrome patients].
    Dordević O; Popović MB; Kostić V
    Srp Arh Celok Lek; 2005; 133(1-2):14-20. PubMed ID: 16053170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action monitoring in major depressive disorder with psychomotor retardation.
    Schrijvers D; de Bruijn ER; Maas Y; De Grave C; Sabbe BG; Hulstijn W
    Cortex; 2008 May; 44(5):569-79. PubMed ID: 18387589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice effects in three-dimensional sequential rapid aiming in Parkinson's disease.
    Smiley-Oyen AL; Worringham CJ; Cross CL
    Mov Disord; 2002 Nov; 17(6):1196-204. PubMed ID: 12465057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor and cognitive aspects of motor retardation in depression.
    Caligiuri MP; Ellwanger J
    J Affect Disord; 2000; 57(1-3):83-93. PubMed ID: 10708819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological motor disorders experienced as religious phenomena: role of abnormal movement monitoring.
    Lauerma H; Tuliharju M
    Brain Cogn; 1998 Feb; 36(1):52-6. PubMed ID: 9500883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Three-dimensional ultrasonic movement analysis of gait and hand-movements in schizophrenic patients].
    Putzhammer A; Perfahl M; Pfeiff L; Müller JL
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S38-42. PubMed ID: 15818519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opening velocity, a novel parameter, for finger tapping test in patients with Parkinson's disease.
    Yokoe M; Okuno R; Hamasaki T; Kurachi Y; Akazawa K; Sakoda S
    Parkinsonism Relat Disord; 2009 Jul; 15(6):440-4. PubMed ID: 19103505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease.
    Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF
    J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visuomotor dependency on an initial fixation target involved in the disorder of visually-guided manual movement in Parkinson's disease.
    Yoshida T; Warabi T; Kato M; Kiriyama K; Yanagisawa N
    Neurosci Res; 2005 Feb; 51(2):167-73. PubMed ID: 15681034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotic symptoms in Parkinson's disease: pathophysiology and management.
    Bosboom JL; Wolters ECh
    Expert Opin Drug Saf; 2004 May; 3(3):209-20. PubMed ID: 15155149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaction time and movement time after embryonic cell implantation in Parkinson disease.
    Gordon PH; Yu Q; Qualls C; Winfield H; Dillon S; Greene PE; Fahn S; Breeze RE; Freed CR; Pullman SL
    Arch Neurol; 2004 Jun; 61(6):858-61. PubMed ID: 15210522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
    Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF
    Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study.
    Elsinger CL; Rao SM; Zimbelman JL; Reynolds NC; Blindauer KA; Hoffmann RG
    J Int Neuropsychol Soc; 2003 Nov; 9(7):1088-98. PubMed ID: 14738289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged practice is of scarce benefit in improving motor performance in Parkinson's disease.
    Agostino R; Currà A; Soldati G; Dinapoli L; Chiacchiari L; Modugno N; Pierelli F; Berardelli A
    Mov Disord; 2004 Nov; 19(11):1285-93. PubMed ID: 15390058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
    Lemay S; Chouinard S; Blanchet P; Masson H; Soland V; Beuter A; Bédard MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):31-9. PubMed ID: 14687854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA; Pavel M; Koudelka C; Carlson NE; Nutt JG
    Clin Neuropharmacol; 2009; 32(2):97-102. PubMed ID: 18978495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.